Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
Swetha Kambhampati(Johns Hopkins University), Charalambos Andreadis(University of California, San Francisco), Teresa Ta(University of California Davis Medical Center), Akshay Sudhindra(Atara Biotherapeutics (United States)), Joseph M. Tuscano(University of California Davis Medical Center), Weiyun Z. Ai(City College of San Francisco), Jesika Reiner(University of California San Diego), Erika Crawford(University of California Davis Medical Center), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Charlie Aoun(University of California, San Francisco), Diem Le(University of California Davis Medical Center), Bita Fakhri(University of California, San Francisco), Erika Cavallone(University of California, San Francisco), Michelle Padilla(University of California San Diego), Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist), Miguel Castillo(Gilead Sciences (United States)), Michelle Martinelli(University of California, San Francisco)
Cited by 8
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523